Little interest from pharma in US FDA's drug naming pilot programme
This article was originally published in SRA
Executive Summary
A two-year, US Food and Drug Administration pilot programme to find the best model for evaluating proposed proprietary names for medicines has drawn a poor response from the pharmaceutical industry1-3.
You may also be interested in...
First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
EMA Works On Defining Metadata From RWD Sources
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
EU Decision Time On Expanded Use Of BMS/Ipsen Pharma Cancer Drug Combo
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: